$ANTH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Anthera Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Anthera Pharmaceuticals Inc. Get notifications about new insider transactions in Anthera Pharmaceuticals Inc for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 134,292 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 1,341,448 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 2,265 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 62,285 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Option Exercise | C | 0.00 | 622,161 | 0 | 0 | |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 7.00 | 2,536 | 17,752 | 20,739 | 18.2 K to 20.7 K (+13.93 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 7.00 | 69,726 | 488,082 | 570,147 | 500.4 K to 570.1 K (+13.93 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 7.00 | 696,503 | 4,875,521 | 5,695,228 | 5 M to 5.7 M (+13.93 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 6.58 | 3,804 | 25,030 | 18,203 | 14.4 K to 18.2 K (+26.42 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 6.58 | 104,567 | 688,051 | 500,421 | 395.9 K to 500.4 K (+26.42 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Grant | A | 6.58 | 1,044,520 | 6,872,942 | 4,998,725 | 4 M to 5 M (+26.42 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 6.58 | 792 | 5,211 | 14,399 | 13.6 K to 14.4 K (+5.82 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 6.58 | 21,788 | 143,365 | 395,854 | 374.1 K to 395.9 K (+5.82 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 6.58 | 217,642 | 1,432,084 | 3,954,205 | 3.7 M to 4 M (+5.82 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 1,788 | 9,387 | 13,607 | 11.8 K to 13.6 K (+15.13 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 49,153 | 258,053 | 374,066 | 324.9 K to 374.1 K (+15.13 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 490,994 | 2,577,719 | 3,736,563 | 3.2 M to 3.7 M (+15.13 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 1,205 | 6,326 | 11,819 | 10.6 K to 11.8 K (+11.35 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 33,142 | 173,996 | 324,913 | 291.8 K to 324.9 K (+11.36 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 5.25 | 331,063 | 1,738,081 | 3,245,569 | 2.9 M to 3.2 M (+11.36 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 3,463 | 0 | 10,614 | 7.2 K to 10.6 K (+48.43 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 95,194 | 0 | 291,771 | 196.6 K to 291.8 K (+48.43 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 950,897 | 0 | 2,914,506 | 2 M to 2.9 M (+48.43 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 4,886 | 0 | 7,151 | 2.3 K to 7.2 K (+215.72 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 134,292 | 0 | 196,577 | 62.3 K to 196.6 K (+215.61 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 1,341,448 | 0 | 1,963,609 | 622.2 K to 2 M (+215.61 %) |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 2,265 | 0 | 2,265 | 0 to 2.3 K |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 62,285 | 0 | 62,285 | 0 to 62.3 K |
| Mar 08 2010 | ANTH | Anthera Pharmaceut ... | VANTAGEPOINT VENTURE ASSOCIATE ... | 10% Owner | Buy | C | 0.00 | 622,161 | 0 | 622,161 | 0 to 622.2 K |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Fritsch Ursula | VP, Glob. Reg. & Co ... | Option Exercise | C | 0.00 | 17,523 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Fritsch Ursula | VP, Glob. Reg. & Co ... | Buy | C | 0.00 | 17,523 | 0 | 73,115 | 55.6 K to 73.1 K (+31.52 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Option Exercise | C | 0.00 | 17,523 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | ODINK DEBRA | VP, Pharmaceutical ... | Buy | C | 0.00 | 17,523 | 0 | 95,928 | 78.4 K to 95.9 K (+22.35 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | M | 1.34 | 120,258 | 161,146 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | A | 7.00 | 18,304 | 128,128 | 18,304 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | A | 7.00 | 12,202 | 85,414 | 12,202 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Option Exercise | C | 0.00 | 481,033 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Grant | A | 7.00 | 165,625 | 1,159,375 | 1,173,896 | 1 M to 1.2 M (+16.43 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Payment of Exercise | F | 7.00 | 23,021 | 161,147 | 1,008,271 | 1 M to 1 M (-2.23 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | M | 1.34 | 120,258 | 161,146 | 1,031,292 | 911 K to 1 M (+13.20 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Grant | A | 6.58 | 215,495 | 1,417,957 | 911,034 | 695.5 K to 911 K (+30.98 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | C | 6.58 | 44,901 | 295,449 | 695,539 | 650.6 K to 695.5 K (+6.90 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | C | 5.25 | 101,301 | 531,830 | 650,638 | 549.3 K to 650.6 K (+18.44 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | C | 5.25 | 68,304 | 358,596 | 549,337 | 481 K to 549.3 K (+14.20 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Leheny A. Rachel | Director | Buy | C | 0.00 | 481,033 | 0 | 481,033 | 0 to 481 K |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | SR VP, Preclinical ... | Option Exercise | C | 0.00 | 17,523 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | Trias Joaquim | SR VP, Preclinical ... | Buy | C | 0.00 | 17,523 | 0 | 174,166 | 156.6 K to 174.2 K (+11.19 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Option Exercise | C | 0.00 | 80,997 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Option Exercise | C | 0.00 | 17,523 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Buy | C | 0.00 | 80,997 | 0 | 98,520 | 17.5 K to 98.5 K (+462.23 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | LOWE CHRISTOPHER P. | CFO & VP of Adminis ... | Buy | C | 0.00 | 17,523 | 0 | 17,523 | 0 to 17.5 K |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | C | 0.00 | 12,980 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Option Exercise | C | 0.00 | 33,960 | 0 | 0 | |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Buy | C | 0.00 | 12,980 | 0 | 61,542 | 48.6 K to 61.5 K (+26.73 %) |
| Mar 05 2010 | ANTH | Anthera Pharmaceut ... | HENNEY CHRISTOPHER S | Director | Buy | C | 0.00 | 33,960 | 0 | 48,562 | 14.6 K to 48.6 K (+232.57 %) |
| Mar 02 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | P | 7.05 | 500 | 3,525 | 663,967 | 663.5 K to 664 K (+0.08 %) |
| Mar 02 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | P | 7.19 | 200 | 1,438 | 663,467 | 663.3 K to 663.5 K (+0.03 %) |
| Mar 02 2010 | ANTH | Anthera Pharmaceut ... | TRUEX PAUL F | President and CEO | Buy | P | 7.18 | 300 | 2,154 | 663,267 | 663 K to 663.3 K (+0.05 %) |